Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: A prospective multicenter phase II trial

Chemotherapy-induced nausea and vomiting (CINV) is a common and debilitating adverse event in cancer chemotherapy [1]. Carboplatin (CBDCA), a second-generation platinum analog, is the key drug in the treatment of thoracic cancers [2]. Several international and national antiemetic guidelines have classified CBDCA as moderate-emetic-risk chemotherapy (MEC) [3 –5]. However, owing to the high emetogenic potential of CBDCA among MEC, the latest guidelines recommend a triplet antiemetic regimen consisting of a 5-hydroxytryptamine type-3 receptor antagonist (5-HT3 RA) combined with dexamethasone (DEX) and a neurokinin-1 receptor antagonist (NK1 RA) accordin g to high-emetic-risk chemotherapy (HEC) for the prevention of CBDCA-induced nausea and vomiting.

Source: Lung Cancer - April 23, 2024 Category: Cancer & Oncology Authors: Hirotoshi Iihara, Masamichi Iwai, Ryo Morita, Yukiyoshi Fujita, Keiko Ohgino, Takuma Ishihara, Chiemi Hirose, Yasuyuki Suzuki, Ken Masubuchi, Hitoshi Kawazoe, Daisuke Kawae, Kanako Aihara, Satoshi Endo, Koichi Fukunaga, Mizuki Yamazaki, Takuya Tamura, Yu Source Type: research